Melanoma & Skin Cancer | Specialty

The OncLive Melanoma & Skin Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of skin cancers, including melanoma, basal cell carcinoma, and more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in melanoma and other skin cancers.

Metastatic Melanoma Brain Metastases

June 28th 2019

BRAF/MEK Inhibitors in Metastatic Melanoma

June 28th 2019

Clinical Trials for Frontline Therapy in Melanoma

June 28th 2019

Frontline Therapy in Melanoma

June 28th 2019

Progression on Adjuvant Therapy

June 28th 2019

Pooled Analysis of Neoadjuvant Therapy

June 28th 2019

Stage III Melanoma: Neoadjuvant Therapy

June 28th 2019

Stage III Melanoma: Changes to Staging System

June 28th 2019

Stage III Melanoma: Personalized Management

June 28th 2019

Stage III Melanoma: Adjuvant Therapy Trials

June 28th 2019

Molecular Testing for Stage III Melanoma

June 28th 2019

Management of Stage III Melanoma

June 28th 2019

Atezolizumab/Cobimetinib Combo Misses PFS Endpoint in BRAF V600 Wild-Type Melanoma

June 21st 2019

The combination of atezolizumab (Tecentriq) and cobimetinib (Cotellic) did not improve progression-free survival compared with pembrolizumab (Keytruda) in patients with previously untreated BRAF V600 wild-type melanoma, missing the primary endpoint of the phase III IMspire170 trial.

Dr. Robert on 5-Year Analysis of Dabrafenib/Trametinib in BRAF V600-Mutant Melanoma

June 4th 2019

Caroline Robert, MD, PhD, head of the Dermatology Unit in Gustave Roussy Cancer Center, Villejuif-Paris, France, discusses results of a 5-year analysis evaluating the long-term effects of dabrafenib (Tafinlar) and trametinib (Mekinist) in patients with BRAF V600–mutant unresectable or metastatic melanoma.

Dr. Johnson on Applications of Immunotherapy in Melanoma

May 30th 2019

Douglas B. Johnson, MD, assistant professor of medicine, Vanderbilt University Medical Center, clinical director, Melanoma Research Program, Vanderbilt-Ingram Cancer Center, discusses applications of immunotherapy in melanoma.

Immunotherapy Lessons Learned in Melanoma May Turn Tide in Other Tumors

May 22nd 2019

The use of immunotherapy in cancer was solidified by the ample activity seen in patients with melanoma.

Dr. Daud Discusses the Immunogenicity of Melanoma

May 17th 2019

Adil Daud, MD, clinical professor, Department of Medicine, director, Melanoma Clinical Research, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the immunogenicity of melanoma.

Dr. Whitman on Expanding the Benefit of Immunotherapy in Solid Tumors

May 17th 2019

Eric Whitman, MD, medical director of Atlantic Health System Cancer Care, Atlantic Health System, discusses ways to expand the benefit of immunotherapy in non-immunogenic solid tumors.

Dr. Sullivan on Immunotherapy Approaches in Melanoma

April 29th 2019

Ryan J. Sullivan, MD, assistant professor of medicine, Harvard Medical School, assistant professor of hematology/oncology, Massachusetts General Hospital, discusses treatment approaches with immunotherapy for patients with melanoma.

Cemiplimab Nears EU Approval for CSCC

April 29th 2019

The European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion recommending approval of cemiplimab for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation, according to Regeneron Pharmaceuticals, the manufacturer of the PD-1 inhibitor.